Volume | 1,609,966 |
|
|||||
News | - | ||||||
Day High | 1.82 | Low High |
|||||
Day Low | 1.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.78 | 1.75 | 1.82 | 1.775 | 1.77 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,025 | 1,609,966 | $ 1.78 | $ 2,866,157 | - | 0.92 - 3.73 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:53:45 | 6 | $ 1.8185 | USD |
Lexicon Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
433.52M | 244.92M | - | 1.2M | -177.12M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lexicon Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.59 | 2.02 | 1.51 | 1.71 | 4,327,696 | 0.19 | 11.95% |
1 Month | 2.04 | 2.09 | 1.48 | 1.70 | 3,316,201 | -0.26 | -12.75% |
3 Months | 3.06 | 3.73 | 1.48 | 2.38 | 4,488,408 | -1.28 | -41.83% |
6 Months | 1.12 | 3.73 | 0.92 | 2.05 | 3,720,514 | 0.66 | 58.93% |
1 Year | 3.56 | 3.73 | 0.92 | 2.02 | 3,046,398 | -1.78 | -50.00% |
3 Years | 4.63 | 6.3299 | 0.92 | 2.44 | 1,540,963 | -2.85 | -61.56% |
5 Years | 7.04 | 9.65 | 0.92 | 3.20 | 1,930,565 | -5.26 | -74.72% |
Lexicon Pharmaceuticals Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |